Relay Therapeutics Shares Surge 60% Over the Past Year as an Investor Acquires Nearly 4 Million Additional Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: NASDAQ.COM
Commodore Capital's Investment: Commodore Capital increased its stake in Relay Therapeutics (NASDAQ: RLAY) by 3.65 million shares in Q3, bringing its total holdings to 17 million shares valued at $88.7 million, which represents 4.3% of its U.S. equity AUM.
Relay Therapeutics Performance: Relay Therapeutics shares have risen 60% over the past year, although they remain nearly 90% below their 2021 highs, highlighting the volatility in early-stage biotech investments.
Company Developments: Relay Therapeutics is focused on developing precision small molecule therapeutics for specific cancers and has made progress in clinical trials while reducing its quarterly net loss and managing expenses effectively.
Market Outlook: The company's improving financial position and ongoing clinical trials are attracting renewed institutional interest, raising questions about its ability to convert pipeline potential into sustainable value for long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RLAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RLAY
Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 14.75 USD with a low forecast of 13.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.650
Low
13.00
Averages
14.75
High
17.00
Current: 7.650
Low
13.00
Averages
14.75
High
17.00
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oppenheimer Upgrades Relay Therapeutics Rating
- Rating Upgrade: Oppenheimer has upgraded Relay Therapeutics (RLAY) from 'perform' to 'outperform', anticipating that its lead asset zovegalisib could benefit if Celcuity's (CELC) gedatolisib data underperforms, with a price target of $14 representing an 88% upside from the January 23 close.
- Data Expectations: Analyst Matthew Biegler believes that the data from the gedatolisib VIKTORIA-1 study will underperform expectations and may even fail, creating a 'beatable bar' for zovegalisib, which could positively impact its market performance.
- Therapeutic Advantages: As a mutant-selective inhibitor, zovegalisib may have advantages over gedatolisib in breast cancer treatment, as key opinion leaders indicate a preference for treatment segmentation based on ESR1 and PI3K mutation statuses, providing a strategic edge for Relay Therapeutics' product.
- Market Outlook: Relay Therapeutics is set to showcase its potential at the upcoming Jefferies London Healthcare Conference, and combined with the analyst's optimistic rating, it may attract more investor attention towards its future growth opportunities.
Continue Reading
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
- Clinical Trial Breakthrough: Oncolytics Biotech's pelareorep achieves a 33% objective response rate in KRAS-mutant metastatic colorectal cancer patients, significantly surpassing the historical benchmark of 6-11%, indicating its potential in cancer treatment.
- Broad Market Outlook: The total addressable market for pelareorep in colorectal cancer is projected to reach $20 billion by 2033, highlighting the drug's significance in addressing unmet medical needs.
- Strategic Planning: The company plans to initiate a controlled study in second-line KRAS-mutant colorectal cancer following consultations with key opinion leaders and regulatory authorities, enhancing the analytical rigor of data to support potential regulatory submissions.
- Expert Endorsement: Dr. Sanjay Goel from Rutgers Cancer Institute emphasizes that a 33% response rate is highly unusual in this setting, underscoring the necessity for further studies and indicating the clinical value of the drug.
Continue Reading